TICKVALE
>⌘K
Nasdaq · CIK 0001635088 · PHARMACEUTICAL PREPARATIONS

ROIVANT SCIENCES LTD.

ROIV chart by TradingView
P/E P/B 6.0xP/SALES 3386.7xEV/EBITDA FCF YIELD -3.22%

PRICE HISTORY

LIVE · NASDAQ
ROIV chart by TradingView
REVENUE FY2025 ENDED MAR 2026
$0.0B
EBITDA
$-0.5B
FREE CASH FLOW
$-0.8B
EPS
$-0.43
GROSS MARGIN
ROIC
Q1 FY26ENDED JUN 2026HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 25 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET

VALUATION

what you pay for a unit of the business7 CHARTS

P / E RATIO (TTM)

-17%
LATEST · Q1 FY26
Q1 FY20Q2 FY21Q3 FY22Q4 FY23Q1 FY25Q1 FY26
1.7x2.1x

P / SALES (TTM)

3386.7x
+1478%
LATEST · Q1 FY26
3386.7xQ1 FY20Q2 FY21Q3 FY22Q4 FY23Q1 FY25Q1 FY26
44.7x3386.7x

P / BOOK

6.0x
+62%
LATEST · Q1 FY26
6.0xQ1 FY20Q2 FY21Q3 FY22Q4 FY23Q1 FY25Q1 FY26
1.5x9.5x

EV / EBITDA (TTM)

-11%
LATEST · Q1 FY26
Q1 FY20Q2 FY21Q3 FY22Q4 FY23Q1 FY25Q1 FY26
0.6x0.7x

EV / REVENUE (TTM)

-1%
LATEST · Q1 FY26
Q1 FY20Q2 FY21Q3 FY22Q4 FY23Q1 FY25Q1 FY26
21.2x200.9x

FCF YIELD (TTM)

-3.22%
+6.0pp
LATEST · Q1 FY26
-3.22%Q1 FY20Q2 FY21Q3 FY22Q4 FY23Q1 FY25Q1 FY26
-39.07%-3.22%

DIVIDEND YIELD (TTM)

LATEST · Q1 FY26
Q1 FY20Q2 FY21Q3 FY22Q4 FY23Q1 FY25Q1 FY26

GROWTH

is the business getting bigger5 CHARTS

REVENUE

$0.0B
-9%
LATEST · Q1 FY26
0.0BQ1 FY20Q2 FY21Q3 FY22Q4 FY23Q1 FY25Q1 FY26

EBITDA (DERIVED)

$-0.4B
$0.1B
LATEST · Q1 FY26
-0.4BQ1 FY20Q2 FY21Q3 FY22Q4 FY23Q1 FY25Q1 FY26

NET INCOME

$-0.2B
$0.2B
LATEST · Q1 FY26
-0.2BQ1 FY20Q2 FY21Q3 FY22Q4 FY23Q1 FY25Q1 FY26

EPS (DILUTED)

$-0.26
$0.14
LATEST · Q1 FY26
-0.26Q1 FY20Q2 FY21Q3 FY22Q4 FY23Q1 FY25Q1 FY26

REVENUE GROWTH YOY

-33.55%
-424.3pp
LATEST · Q1 FY26
-33.55%Q1 FY20Q2 FY21Q3 FY22Q4 FY23Q1 FY25Q1 FY26
-193.22%957.22%

PROFITABILITY & RETURNS

what survives to the bottom, and what it earns on capital4 CHARTS

FCF MARGIN

-18788.00%
-11714.8pp
LATEST · Q1 FY26
-18788.00%Q1 FY20Q2 FY21Q3 FY22Q4 FY23Q1 FY25Q1 FY26
-18788.00%7612.05%

RETURN ON CAPITAL

+4952.1pp
LATEST · Q1 FY26
Q1 FY20Q2 FY21Q3 FY22Q4 FY23Q1 FY25Q1 FY26
-5190.83%5882.47%

RETURN ON EQUITY (TTM)

-6.29%
+38.7pp
LATEST · Q1 FY26
-6.29%Q1 FY20Q2 FY21Q3 FY22Q4 FY23Q1 FY25Q1 FY26
-130.35%93.35%

MARGIN FUNNEL

every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the business
GROSS MARGIN
OPERATING MARGIN-25380.93%
NET MARGIN-13164.84%
FCF MARGIN-18788.00%
38781.5121282.663783.82-13715.03-31213.88OPERNETFCFQ1 FY20Q4 FY20Q3 FY21Q2 FY22Q1 FY23Q4 FY23Q3 FY24Q2 FY25Q1 FY26

CASH & CAPITAL

where the money actually goes5 CHARTS

FREE CASH FLOW

$-0.3B
$0.2B
LATEST · Q1 FY26
-0.3BQ1 FY20Q2 FY21Q3 FY22Q4 FY23Q1 FY25Q1 FY26

STOCK-BASED COMP

$0.1B
+484%
LATEST · Q1 FY26
0.1BQ1 FY20Q2 FY21Q3 FY22Q4 FY23Q1 FY25Q1 FY26

CAPITAL EXPENDITURE

$0.0B
+37%
LATEST · Q1 FY26
0.0BQ1 FY20Q2 FY21Q3 FY22Q4 FY23Q1 FY25Q1 FY26

SHARES OUTSTANDING

0.72B
+11%
LATEST · Q1 FY26
0.72BQ1 FY20Q2 FY21Q3 FY22Q4 FY23Q1 FY25Q1 FY26

DIVIDEND / SHARE

LATEST · Q1 FY26
Q1 FY20Q2 FY21Q3 FY22Q4 FY23Q1 FY25Q1 FY26

BALANCE SHEET

how much cushion there is3 CHARTS

CASH & EQUIVALENTS

$1.2B
-39%
LATEST · Q1 FY26
1.2BQ1 FY20Q2 FY21Q3 FY22Q4 FY23Q1 FY25Q1 FY26

TOTAL DEBT

+90%
LATEST · Q1 FY26
Q1 FY20Q2 FY21Q3 FY22Q4 FY23Q1 FY25Q1 FY26

DEBT / EBITDA (TTM)

-28%
LATEST · Q1 FY26
Q1 FY20Q2 FY21Q3 FY22Q4 FY23Q1 FY25Q1 FY26
0.1x0.1x

OWNERSHIP

10 LARGEST HOLDERS · WHO OWNS THE FLOAT
INSTITUTIONS 77.24%INSIDERS 21.45%OTHER / RETAIL 1.31%628 INSTITUTIONAL FILERS
HOLDER% HELDSHARESVALUECHANGE
FMR, LLC10.79%78.0M$2.83B+18.6%
Morgan Stanley7.17%51.8M$1.88B-11.2%
Blackrock Inc.6.13%44.3M$1.61B+7.5%
QVT Financial LP3.48%25.2M$914.4M-4.7%
UBS Group AG3.13%22.6M$822.0M+23.0%
Vanguard Capital Management LLC2.86%20.7M$751.5MNEW
Vanguard Portfolio Management LLC2.75%19.8M$720.9MNEW
State Street Corporation2.24%16.2M$588.2M-6.8%
Adage Capital Partners GP L.L.C.1.77%12.8M$464.9M+19.8%
Goldman Sachs Group Inc1.54%11.1M$403.8M+1.2%
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.